A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
Public ClinicalTrials.gov record NCT07091630. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emnergize
Study identification
- NCT ID
- NCT07091630
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 160 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 15, 2025
- Primary completion
- Oct 6, 2027
- Completion
- Jan 22, 2031
- Last update posted
- Aug 20, 2026
2025 – 2031
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham - 1720 University Blvd | Birmingham | Alabama | 35233 | Active, not recruiting |
| Samir Macwan, M.D., Inc. (S corporation) | Rancho Mirage | California | 92270 | Recruiting |
| Colorado Springs Neurological Associates | Colorado Springs | Colorado | 80907 | Recruiting |
| Medstar Health Research Institute | Washington D.C. | District of Columbia | 20010 | Recruiting |
| Gables Neurology | Miami | Florida | 33133 | Recruiting |
| Aqualane Clinical Research | Naples | Florida | 34105 | Recruiting |
| Paradigm Health System | Slidell | Louisiana | 70458 | Recruiting |
| Penn Medicine University City | Philadelphia | Pennsylvania | 19104-5545 | Recruiting |
| Jefferson Health Honickman Center | Philadelphia | Pennsylvania | 19107 | Recruiting |
| National Neuromuscular Research Institute | Austin | Texas | 78756 | Recruiting |
| NeuroCarePlus | Houston | Texas | 77094 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 66 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07091630, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 20, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07091630 live on ClinicalTrials.gov.